北京招聘

具备较强的工作计划能力、学习能力、协调沟通能力、执行能力，开展医药企业政策及战略研究任务，维护和拓展与政府、行业协会和相关企业关系、组织开展项目申报、企业宣传等相关活动。

主要职责：

1.把握国家宏观经济政策，分析和评估宏观经济和医药行业发展对企业造成的影响，发现主要发展机会与主要风险；

2. 研究生物医药等行业相关政策及法律法规，收集医药及相关行业市场信息，支持公司各部门战略决策；

  3. 维护并开拓与政府、行业学、协会以及相关企业的关系，为公司发展创造良好的外部环境；

4. 有较强的政策研究报告撰写和口头表达能力，有较强的团队精神和沟通能力；

5. 协助公司进行政府项目申报或新药注册审评；

6.领导交办的其他工作。

Academic / Professional Qualification 学历要求

    

    

大学全日制本科或硕士研究生以上学历，药学、医学、生物工程或管理学类等相关专业。

    

    

Technical / Skills Training技术资质

    

    

良好的计划组织、公关能力及公文写作、中英文语言表达能力，熟练掌握Office等办公软件。

    

    

Working Experience工作经验

    

    

1-3年以上行业内相关工作经历；责任感与服务意识；具有跨国医药外企相关部门、国家相关部委或部委直属政策研究机构、医药相关行业协会等工作经验者优先，熟悉新药注册法规与申报、具有与国家政府部门对接经历者优先。

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.